THE BEST SIDE OF ABBV-744 CLINICAL TRIAL PHASE 2 DATA

In Section C, individuals will receive ABBV-744 and oral navitoclax. In Segment D, participants will get ABBV-744 and ruxolitinib. Contributors will obtain treatment until eventually ailment progression or the individuals are unable to tolerate the study drugs.Probable new strategies for that prognosis and treatment of AML. (A) The identification o